Roche

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Roche and other ETFs, options, and stocks.

About RHHBY

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. 

CEO
Thomas Schinecker
CEOThomas Schinecker
Employees
112,774
Employees112,774
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1896
Founded1896
Employees
112,774
Employees112,774

RHHBY Key Statistics

Market cap
335.14B
Market cap335.14B
Price-Earnings ratio
20.70
Price-Earnings ratio20.70
Dividend yield
1.98%
Dividend yield1.98%
Average volume
1.86M
Average volume1.86M
High today
$51.88
High today$51.88
Low today
$50.74
Low today$50.74
Open price
$51.04
Open price$51.04
Volume
409.34K
Volume409.34K
52 Week high
$60.85
52 Week high$60.85
52 Week low
$37.51
52 Week low$37.51

RHHBY News

TipRanks 19h
OraSure announces FDA clearance of Colli-Pee Dx Urine Collection Kit

OraSure (OSUR) announced FDA clearance of its Colli-Pee Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche’s (RHHBY) tests for Chl...

TipRanks 22h
Roche announces EU IVDR approval of several Ventana label expansions

Roche (RHHBY) announced the European Union In Vitro Diagnostic Regulation, or IVDR, approval of several label expansions for the Ventana MMR RxDx Panel, an immu...

Simply Wall St 3d
Roche Expands BTK Degradation Platform With Nurix In Multi‑Area Bet - simplywall.st

...

Roche Expands BTK Degradation Platform With Nurix In Multi‑Area Bet - simplywall.st

Analyst ratings

50%

of 22 ratings
Buy
50%
Hold
40.9%
Sell
9.1%

More RHHBY News

Seeking Alpha 3d
Roche keeps €600M Germany project on track despite industry concerns - report

Roche (RHHBY) said it will proceed with its planned €600M investment in a new diagnostics production facility in Penzberg, Germany, despite concerns over the Ge...

Roche keeps €600M Germany project on track despite industry concerns - report
Barron's 4d
This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug

Biotech and Pharma This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug In this article NRIX RHHBY SPX Nurix Therapeutics landed a $2.3...

This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug
TipRanks 4d
Nurix Therapeutics downgraded to Equal Weight at Wells Fargo after Roche deal

As previously reported, Wells Fargo downgraded Nurix Therapeutics (NRIX) to Equal Weight from Overweight with a price target of $25, down from $28. While the ec...

TipRanks 4d
Nurix Therapeutics Stock Soars 40% After $2.3B Blood Cancer Deal with Roche

Shares in biopharmaceutical company Nurix Therapeutics (NRIX) soared nearly 40% in pre-market trading after sealing a $2.3 billion blood cancer deal with Swiss...

Nasdaq 4d
Roche And Nurix Ink $2.3 Bln Collaboration To Co-Develop BTK Degrader Bexobrutideg

(RTTNews) - Roche (RHHBY) announced it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. (NRIX). The two compani...

Roche And Nurix Ink $2.3 Bln Collaboration To Co-Develop BTK Degrader Bexobrutideg

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.